Company Profile
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, sterile filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Further, it offers low-molecular-weight heparin, Okedi, and Rolcya; and develops Letrozole SIE and Risperidone QUAR. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Pozuelo de Alarcón, Spain. Laboratorios Farmaceúticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.
Latest News
3Shape's TRIOS MOVE Pro Scanner Cart Wins Red Dot 2026 Design Award
AI Usage Among 7th Gen Galaxy Foldables Users Grows in Southeast Asia and Oceania as Mobile Continues to be the Primary Gateway to AI
Take Five: A crude summer
Bank of England to keep rate steady despite oil and gas price rebound
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Website | https://www.rovi.es |
| Audit Risk | 6 |
| Board Risk | 4 |
| Overall Risk | 2 |
| Market Cap | 3.03B |
| Trailing P/E | 16.38 |
| Forward P/E | 17.56 |
| Dividend Rate | 0.96 |
| Dividend Yield | 1.63% |
| Trailing Annual Div. Rate | 0.96 |
| Trailing Annual Div. Yield | 1.63% |
| Trailing EPS | 3.62 |
| Forward EPS | 3.38 |
| Book Value | 13.18 |
| Price-to-Book | 4.5 |
| Enterprise-to-Revenue | 3.89 |
| Enterprise-to-EBITDA | 17.07 |
| Ex-Dividend Date | 07/13/2026 |
| Earnings Date | 07/23/2026 |
| Earnings Call Date | 07/23/2026 |